Asia Spotlight: Emerging Markets At Stake As Viehbacher Departs Sanofi?
As emerging markets represent 32% of Sanofi’s overall sales, the highest among big pharma firms, will the sudden departure of Viehbacher leave a dent in one of the firm’s key growth platforms?
You may also be interested in...
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?
China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.